Chemkart India Ltd

Chemkart India Limited: Trading Window closed from 1 October 2026 till 48 hours after the declaration of Un-Audited Standalone and Consolidated Financial Results for the half year ended 30 September 2026

AGM Details

• Date, time, mode: 19 Sep 2026 at 12:00 PM IST via VC/OAVM.
• End time: 12:34 PM IST.
• Record date: 12-09-2026; 862 shareholders on record.
• Remote e-voting window: 16–18 Sep 2026; venue voting at AGM.
• Shareholders present via VC: promoters 3, public 8.

Key Resolutions

• Resolution 01: Adoption of annual audited financial statements (Ordinary).
• Resolution 02: Re-appointment of Shailesh Vinodrai Mehta as director by rotation.
• Resolution 03: Appointment of statutory auditors for next term; remuneration to be fixed.
• Resolution 04: Appointment of secretarial auditor for next term; remuneration to be fixed.

Voting results

• Resolution 01: Passed; 100% in favor.
• Resolution 02: Passed; 100% in favor.
• Resolution 03: Passed; 100% in favor.
• Resolution 04: Passed; 100% in favor.

Appointments & Remuneration

• Statutory auditors appointed for next term; remuneration to be fixed.
• Secretarial auditors appointed for next term; remuneration to be fixed.
• Director: Shailesh Mehta re-appointed by rotation.

AGM Details

• AGM held on 19 September 2026 at 12:00 PM IST via VC/OAVM.
• Concluded at 12:34 PM IST.
• Quorum present; proxy facility not available; authorized representatives may attend.

Key Resolutions

• Adoption of the annual audited financial statements and reports.
• Appointment of Mr. Shailesh Vinodrai Mehta as a Director retiring by rotation.
• Appointment of Statutory Auditors from the conclusion of 7th AGM to the conclusion of 12th AGM and to fix their remuneration.
• Appointment of Secretarial Auditor from the conclusion of 7th AGM to the conclusion of 12th AGM and to fix remuneration.

Voting Results

• Voting results to be submitted later; Scrutinizer's report pending.

Director Changes

• Mr. Shailesh Vinodrai Mehta to be appointed as director retiring by rotation.

Auditor Appointments

• Statutory auditors appointed from AGM conclusion to 12th AGM; remuneration to be fixed.
• Secretarial auditor appointed for the same period; remuneration to be fixed.

Target overview

• Target: Easy Raw Materials Private Limited, a private Indian company trading pharma products and nutritional supplements.
• Country of incorporation: India; presence primarily in pharma and nutritional sectors.
• Industry: Trading of pharma products and nutritional supplements.

Transaction details

• Investment amount: Rs 1.30 crore via rights issue.
• Equity shares issued: 13,00,000 at Rs 10 face value.
• Form of consideration: cash.
• Post-allotment paid-up capital: Rs 9.81 crore; 98,10,000 shares.
• Pre- and post-allotment holding: 100% ownership before and after.
• Total investment cost: Rs 1.30 crore.

Related party & governance

• ERML is a wholly owned subsidiary; related party transaction; arms-length.
• Company holds 100% stake; no other interests.
• Arrangement aligns with IPO proceeds utilization.

Rationale & use of proceeds

• Purpose: utilize IPO proceeds toward commissioning the subsidiary's manufacturing unit.
• Strategic rationale: strengthens subsidiary funding within the group.

Regulatory & timing

• Regulatory approvals: Not applicable.
• Indicative completion: Not applicable.
• Timing: Not specified.

Target background

• Incorporated in 2020; operates in pharma and nutritional products trading.
• Turnover last three years: NIL.
• Loss after tax Rs 59.47 Lakh; Net worth Rs 578.60 Lakh.
• Country of incorporation: India.

CFO Resignation

• Basavaraj Shankar Dalawai resigned as CFO effective 10 Sep 2026 due to internal restructuring.
• He confirmed no other material reasons beyond those in his resignation letter.
• He ceases to be Key Managerial Personnel effective 10 Sep 2026.

CFO Appointment

• Mohammad Asim Siddiqui appointed CFO effective 11 Sep 2026.
• Term not applicable; he designated as Whole-Time KMP.
• Over 16 years in Finance, MIS, Compliance, Internal Controls; LL.B., MBA, M.Com.
• Not related to directors; NIL shareholding; not debarred.
• Date of appointment: 10 Sep 2026; effective 11 Sep 2026.
• Recommended by Audit Committee and Nomination & Remuneration Committee.

Financials

• Standalone revenue from operations: INR 21,259.48 lakh; up 4.58% YoY to INR 214.66 crore.
• Standalone net profit after tax: INR 20.77 crore.
• Standalone EBITDA: INR 28.94 crore; margin 13.61%.
• Consolidated revenue from operations: INR 21,482.91 lakh.
• Consolidated PAT: INR 19.65 crore.
• Standalone EPS: INR 18.24; Consolidated EPS: INR 17.26.
• DOI: IPO raised INR 8,008.42 lakh; SME listing on 14 July 2025.
• Dividend not declared for the financial year 2025-26.
• Reserves and surplus: standalone INR 11,895.90 lakh; consolidated INR 11,763.08 lakh.
• Paid-up share capital: INR 1,209.90 lakh; Authorized capital: INR 2,500 lakh.
• Subsidiaries: Easy Raw Materials Pvt Ltd and Vinstar Biotech Pvt Ltd, 100% each.

Capital & liquidity

• Cash and cash equivalents: consolidated INR 3,864.54 lakh; standalone INR 3,649.48 lakh.
• Short-term borrowings: INR 495.28 lakh; long-term borrowings: INR 10.20 lakh.
• IPO proceeds utilized: capex INR 457.00 lakh; debt repayment INR 2,000.00 lakh.
• General corporate purpose: INR 954.00 lakh.
• Authorized share capital unchanged at INR 2,500 lakh; issued capital INR 1,209.90 lakh.

Operations & capacity

• Kalher, Bhiwandi facility spans 28,259 sq ft with 540 MT grinding and 450 MT blending capacity.
• Subsidiaries: Easy Raw Materials Pvt Ltd; Vinstar Biotech Pvt Ltd, both wholly owned.
• Backward integration through subsidiaries strengthens nutraceutical value chain.

IPO & ownership

• IPO: 26,00,000 new shares; issue price INR 248; OFS 6,29,200 shares.
• Listing on BSE SME on 14 July 2025; debut price INR 250; 0.8% premium.

Governance & leadership

• Board comprises six directors; three independent; MD and two executive directors.
• Audit Committee: three independent directors; six meetings; chair Rajesh V. Kalro.
• Company Secretary Shreya Dalmia appointed 20 Jan 2026; Ramdulari Saini resigned 01 Nov 2025.
• CSR Committee: three members; one meeting during the year.
• Secretarial audit: no qualifications reported.

Risks & outlook

• Risks: raw material cost, currency fluctuations, regulatory changes; working capital intensity.
• Outlook: FY2026-27 focuses on processing capacity, subsidiary integration, and expanded product portfolio.
• Domestic demand supportive; nutraceutical growth driven by health awareness and sports nutrition adoption.

CSR & ESG

• CSR spend: INR 43.41 lakh; 2% average net profit threshold INR 43.53 lakh.
• Actual CSR spend: INR 44.41 lakh; closing balance INR -1.63 lakh.
• CSR projects include healthcare and livelihood initiatives in Maharashtra.

Financial highlights

• Standalone Revenue from Operations: ₹21,259.48 lakh; up 4.58% YoY.
• Standalone Total Income: ₹21,355.73 lakh; YoY growth ~3.94%.
• Standalone EBITDA: ₹28.94 crore; margin 13.61%.
• Standalone PAT: ₹2,077.20 lakh; PAT margin ~9.77%.
• Consolidated Total Income: ₹21,549.41 lakh; YoY growth ~4.74%.
• Consolidated PAT: ₹1,965.82 lakh; margin ~9.00%.

IPO & capital structure

• IPO raised ₹8,008.42 lakh; mix of fresh issue and promoter sale.
• Equity share capital up to 12.099 crore shares; paid-up ₹12,09.90 lakh.
• Authorized capital unchanged at ₹25 crore; SME BSE listing on 14 Jul 2025.
• Promoters Ankit and Parul Mehta held ~36.7–36.8% each.
• IPO proceeds utilized as per offer document; no deviation.

Operations & growth

• Backward integration via wholly-owned Easy Raw Materials and Vinstar Biotech.
• Grinding capacity ~540 MT/yr; blending capacity ~450 MT/yr at Bhiwandi facility.
• Product portfolio spans seven nutraceutical categories; supports growth.
• FY26 revenue from operations grew 4.58% to ₹214.66 crore.

Governance & risk

• Board comprises six directors; three independent.
• Audit, Nomination & Remuneration, CSR, and Stakeholders Relationship committees.
• Risk management framework covers supply, regulatory, FX, and compliance.
• Independent Directors held a separate meeting on 9 March 2026.

Audits & internal controls

• Statutory auditors: Prem Chand Jain & Co for 2026-31; INR 3.90 lakh.
• Previous auditor Bagaria & Co LLP; internal audit by NR Tibrewala; 2026-27 by Vinay Bhushan.
• Secretarial auditor: Nirmal Tiwari & Associates for 2026-31.

CSR & ESG

• CSR obligation: 2% of average net profit; 2025-26 CSR expense ₹43.53 lakh.
• FY25-26 CSR spend ₹44.41 lakh; health and livelihood projects.

Subsidiaries & related party

• Subsidiaries: Easy Raw Materials Pvt. Ltd. and Vinstar Biotech Pvt. Ltd.; 100% owned.
• Related party transactions approved by Audit Committee; arms-length and in ordinary course.
• Significant related party balances and loans disclosed in notes.

AGM Details

• AGM date/time: 19 September 2026 at 12:00 PM IST via VC/OAVM.
• Remote e-voting window: 16 Sep 2026 09:00 IST to 18 Sep 2026 17:00 IST.
• Cut-off date for eligibility: 12 September 2026.

Resolutions

• Adoption of Audited Standalone and Consolidated Financial Statements for year ended 31 March 2026.
• Reappointment of Shailesh Vinodrai Mehta as Director retiring by rotation.
• Appointment of Statutory Auditors: Prem Chand Jain & Co. for 2026-31; remuneration to be mutually agreed.
• Appointment of Secretarial Auditor: Nirmal Tiwari & Associates for 2026-31; remuneration INR 75,000 plus taxes.
• Board authorized to implement these resolutions.

Director changes

• Executive Director Shailesh Mehta reappointed by rotation.
• Mehta first appointed 04 Jul 2024; became Executive Director 30 Sep 2024.
• Remuneration last drawn by Mehta: Nil.

Auditors

• Statutory Auditor: Prem Chand Jain & Co for 2026-31; remuneration INR 3.90 Lakh p.a. plus GST.
• Secretarial Auditor: Nirmal Tiwari & Associates for 2026-31; remuneration INR 75,000 plus taxes.

Other approvals

• Board authorized to implement these resolutions.